Ze Zhang, MD
Ophthalmology · New Orleans, LANPI 1811239940
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $33,749 of the $44,057 with a category attached, or 76.6%. Alcon accounts for 61.4% of it on its own, with 21 other manufacturers making up the rest. Among ophthalmology clinicians in LA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 224 payments — averaging $196.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alcon$27K
- Aerie Pharmaceuticals, Inc.$7K
- Sight Sciences, Inc.$5K
- AbbVie$2K
- Glaukos Corporation$2K
- Bausch & Lomb, A Division Of Bausch Health US, LLC$317
- plus $840 from 16 others
Across 10 payments — averaging $5848.40 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$58K
What the payments were for
- Consulting fees$3,4008%
- Speaking & faculty fees$33,74977%
- Food & beverage$6,83516%
- Education$430%
- Gifts$300%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alcon | 71 | $27,059 |
| Aerie Pharmaceuticals, Inc. | 21 | $7,127 |
| Sight Sciences, Inc. | 10 | $5,175 |
| AbbVie(2 entities) | 71 | $1,860 |
| Glaukos Corporation | 8 | $1,679 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 13 | $317 |
| AstraZeneca | 1 | $124 |
| Johnson & Johnson Surgical Vision, Inc. | 1 | $116 |
| NEW World Medical,inc. | 3 | $102 |
| Bausch & Lomb Americas Inc. | 4 | $70 |
| Sun Pharmaceutical Industries Inc. | 3 | $63 |
| Dompe US, Inc. | 2 | $61 |
| Novartis | 3 | $51 |
| Biotissue Holdings Inc. | 3 | $51 |
| Harrow Eye, LLC | 2 | $50 |
| Omeros Corporation | 2 | $32 |
| Merz North America, Inc. | 1 | $30 |
| Carl Zeiss Meditec USA, Inc. | 1 | $23 |
| Ocular Therapeutix, Inc. | 1 | $19 |
| Rayner Intraocular Lenses Limited | 1 | $18 |
| Amgen | 1 | $17 |
| ANI Pharmaceuticals, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Rhopressa$27,562
- Rocklatan$26,137
- OMNI(R) SURGICAL SYSTEM (US)$5,000
- Hydrus Microstent$4,921
- SIMBRINZA$4,234
- iStent Trabecular Micro-Bypass Stent System$1,000
- iDoseTR$199
- XEN$125
- LUMIGAN$125
- ULTOMIRIS$124
- ENVISTA$123
- STELLARIS$123
- Clareon$122
- Tecnis 1-piece IOL$116
- XEN GLAUCOMA TREATMENT SYSTEM$114
- iStent inject Trabecular Micro-Bypass Stent System$112
- DURYSTA$102
How this compares
$44,057 in reported general payments places this provider in the 95th percentile of 286 ophthalmology providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RocklatanNetarsudil Mesylat/Latanoprost | 418 | $188,068 |
| RhopressaNetarsudil Mesylate | 268 | $119,570 |
| CombiganBrimonidine Tartrate/Timolol | 146 | $53,667 |
| RestasisCyclosporine | 51 | $45,445 |
| LumiganBimatoprost | 111 | $45,158 |
| Brimonidine Tartrate | 696 | $21,312 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 71 | $20,806 |
| Alphagan PBrimonidine Tartrate | 37 | $17,392 |
| Restasis MultidoseCyclosporine | 22 | $15,691 |
| Travoprost | 81 | $13,425 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 990 | $12,989 |
| VyzultaLatanoprostene Bunod | 24 | $11,313 |
| Latanoprost | 1,269 | $9,482 |
| Prednisolone Acetate | 234 | $9,226 |
| Dorzolamide-TimololDorzolamide/Timolol/Pf | 69 | $7,977 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Aerie Pharmaceuticals, Inc.Rocklatan, Rhopressa | $7,127 | $307,638686 claims |
| AbbVieCombigan, Restasis, Lumigan, Alphagan P, Restasis Multidose | $1,860 | $177,353367 claims |
| AlconSimbrinza | $27,059 | $20,80671 claims |
| Bausch & Lomb Americas Inc.Vyzulta | $70 | $11,31324 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 286 ophthalmology providers in Louisiana.
Other ophthalmology in New Orleans
- Rebecca MetzingerNew Orleans$63K
- Peter KastlNew Orleans$32K
- Benjamin LeeNew Orleans$7K
- Glen CangelosiNew Orleans$6K
- Matthew BoltonNew Orleans$5K
- Barry LeaderNew Orleans$5K
- Blake WilliamsonBaton Rouge$443K
- Wyche ColemanShreveport$35K
- Bryan VekoviusShreveport$29K
- Christopher ShelbyShreveport$27K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.